Bypass and Angioplasty Investigation (BARI) puts polymerase transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) on equal footing
This article was originally published in Clinica
Almost 90% of severe heart disease patients survive at least five years after PTCA or bypass surgery but bypass gives the greatest short-term improvement in quality of life, according to follow-up data from BARI (Bypass and Angioplasty Investigation). The study, presented at the AHA annual meeting (Anaheim, California. November 13th-16th) also confirmed previous research which has shown higher mortality for diabetics on drug treatment after PTCA (see table).
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.